-
2022-503092-28-00
5
2024-01-08
Relapsed/Refractory Follicular Lymphoma
-
2022-502775-29-01
5
2023-12-14
Early stage Follicular Lymphoma
-
2023-509793-38-00
4
2023-11-24
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or CLL-like mo
-
2023-503295-25-00
10
2023-10-31
Resectable biliary tract cancers
-
2023-503661-28-00
5
2023-10-26
Hidradenitis Suppurativa
-
2022-501810-77-00
5
2023-09-01
Relapsed or Refractory Marginal Zone Lymphoma
-
2024-513562-19-00
5
2023-08-30
End-Stage Kidney Disease
-
2023-510431-11-00
4
2023-07-21
Chronic Lymphocytic Leukemia
-
2022-501308-90-00
4
2023-05-24
Molecularly selected and resectable primary colorectal cancer
-
2024-512878-98-00
9
2023-05-16
Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative
Breas
-
2023-507396-21-00
4
2023-03-16
transfusion-dependent α- or β-thalassemia or low-risk myelodysplastic
-
2022-501894-37-00
4
2023-03-02
prostate cancer
-
2024-518937-26-00
4
2023-02-21
Patients with non-metastatic muscle invasive bladder cancer
-
2023-507278-41-00
5
2023-02-10
Familial hypercholsterolemia
-
2023-510384-36-00
5
2022-09-13
Newly Diagnosed Multiple Myeloma
-
2023-504660-41-00
4
2022-07-11
Cholestatic Pruritus in Patients with Primary Biliary Cholangitis (PBC
-
2024-513168-24-00
4
2022-06-01
HIV & Obesity
-
2024-515681-14-00
4
2022-05-02
Stage II (pT4)/III colorectal cancer with positive circulating tumor D
-
2024-510898-24-00
4
2022-01-14
Patients with well differentiated neuroendocrine neoplasia (NENs) not
-
2023-508094-88-00
5
2021-02-08
breast cancer
-
2023-510515-19-00
5
2020-11-27
Higher-risk-myelodysplastic syndromes
-
2024-519007-10-00
10
2020-10-22
Locally advanced stage II/III rectal cancer
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2024-518623-30-00
6
2020-10-01
metastatic castration resistant prostate cancer without mutations of B